Ray Gilmartin faces a dilemma. His company's credibility has been damaged by the recent withdrawal of Vioxx, a multi-billion dollar drug. Moreover, the withdrawal of Vioxx would imply that Merck would fail to meet analysts' earnings expectations for 2005 unless Gilmartin cuts the R&D budget. Cutting the budget might hurt morale and productivity in Merck labs.

【書誌情報】

ページ数：5ページ

サイズ：A4

商品番号：HBSP-611027

発行日：2010/9/24

登録日：2012/7/17